43.19
price up icon0.47%   0.20
after-market アフターアワーズ: 43.19
loading

Cytokinetics Inc (CYTK) 最新ニュース

pulisher
Mar 30, 2025

Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Marketscreener.com

Mar 29, 2025
pulisher
Mar 25, 2025

Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - MSN

Mar 25, 2025
pulisher
Mar 20, 2025

Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times

Mar 20, 2025
pulisher
Mar 19, 2025

Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Cytokinetics EVP Malik sells $87,160 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma

Mar 17, 2025
pulisher
Mar 17, 2025

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com

Mar 17, 2025
pulisher
Mar 15, 2025

Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK

Mar 15, 2025
pulisher
Mar 14, 2025

Cytokinetics’ EVP sells $4,500 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Why Have Cytokinetics Stocks Plummeted? - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics Executives Engage in Stock Transactions - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks

Mar 06, 2025
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):